Nov 18, 2020 / 02:50PM GMT
Timothy Minton Anderson - Wolfe Research, LLC - MD of Equity Research
Okay. Good morning. Thanks for joining us. I'm Tim Anderson, the large-cap pharma and large-cap biotech analyst at Wolfe Research. And for the next 45 minutes, we'll be talking with Pfizer's Angela Hwang, who is President of Pfizer's Biopharmaceutical business, which is basically the entire business now. She's been in this role for about the last 2 years, but she's been with Pfizer for 23 years working across lots of geographies and therapeutic areas and business functions. So thank you, Angela, for joining us.
Questions and Answers:
Timothy Minton Anderson - Wolfe Research, LLC - MD of Equity ResearchWe're going to just jump into questions here. I thought maybe we could start with the Upjohn separation. So it officially occurred just this week. Viatris began trading, I think it was yesterday. You ran that division at one point back when it was called Essential Health. Now it was called Upjohn, and now it's part of Viatris. What will finally splitting that out allow the remaining Pfizer
Trustpilot
